ArticleCancers2022

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.

Julia Katharina Schwarze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.